-transparent.png){kind=logo}
In summary, this brief report documents the cell culture and rAHF purification systems used to produce rFVIII and has focused on the unique characteristics of the cell line, the production process, and purification system used. This review emphasizes the general philosophy used throughout the research and development of this innovative and complex therapeutic agent, in order to provide a safe and efficacious rAHF in the management of individuals with hemophilia A. This review provides a brief description of the in-process system and controls that have been incorporated to meet the high standards and safety objective.
Related Publications
E Gomperts, and
R Lundblad, and
R Adamson
September 2000,
Haemophilia : the official journal of the World Federation of Hemophilia,
E Gomperts, and
R Lundblad, and
R Adamson
April 2001,
Seminars in hematology,
E Gomperts, and
R Lundblad, and
R Adamson
January 1994,
Annals of hematology,
E Gomperts, and
R Lundblad, and
R Adamson
December 1999,
Thrombosis and haemostasis,
E Gomperts, and
R Lundblad, and
R Adamson
October 1992,
Transfusion medicine reviews,
E Gomperts, and
R Lundblad, and
R Adamson
September 1991,
Annals of hematology,
E Gomperts, and
R Lundblad, and
R Adamson
October 1992,
Transfusion medicine reviews,
E Gomperts, and
R Lundblad, and
R Adamson
June 2000,
Thrombosis and haemostasis,
E Gomperts, and
R Lundblad, and
R Adamson
April 2002,
Thrombosis and haemostasis,
E Gomperts, and
R Lundblad, and
R Adamson
July 2015,
Biologicals : journal of the International Association of Biological Standardization,
